Project Grant R34HL182386
Award Date 7/15/26
Completion Date 6/30/29
Dollars Obligated $255K
Federal Agency
Federal Grant Program
Assistance Type
Project Grant
Place of Performance
Houston, TX 77030, USA
Similar Awards
- Grant Award Summary The National Heart, Lung, and Blood Institute (NHLBI) awarded a $1,282,827 Project Grant to the University of California, Los Angeles (UCLA) on July 10, 2026, under the Cardiovascular Diseases Research program (CFDA 93.837). This grant supports a multicenter, randomized, placebo-controlled mechanistic trial evaluating the impact of glucagon-like peptide-1 receptor agonist (GLP1-RA) using oral semaglutide on HIV-associated atherosclerosis. The research will enroll 125...
- Summary of Federal Project Grant Award The National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) awarded the University of Texas Health Science Center at Houston $1.93 million under the Diabetes, Digestive, and Kidney Diseases Extramural Research program (CFDA 93.847) effective September 15, 2025, through August 31, 2028. The REINFORCE trial investigates semaglutide microdosing as a maintenance strategy to sustain cardiometabolic and weight-loss benefits in people living...
- Grant Award Summary Beth Israel Deaconess Medical Center, Inc. (BIDMC) received a $1,725,948 Project Grant from the National Heart, Lung, and Blood Institute (NHLBI) under the Cardiovascular Diseases Research program (CFDA 93.837) effective July 15, 2026, with completion targeted for June 30, 2028. The award funds real-world effectiveness and value research on glucagon-like peptide-1 receptor agonists (GLP-1RAs) for prevention of cardiovascular disease among individuals with...
- Federal Grant Award Summary The National Heart, Lung, and Blood Institute (NHLBI) awarded the University of Florida Division of Sponsored Research a Project Grant of $782,085 (awarded June 25, 2026; completion February 28, 2031) under the Cardiovascular Diseases Research program (CFDA 93.837). This project will deliver research services focused on identifying actionable multilevel intervention strategies to improve cardiovascular health among people with HIV (PWH). The research will employ...
- Federal Project Grant Summary The National Heart, Lung, and Blood Institute (NHLBI) awarded a $730,276 project grant (CFDA 93.837 – Cardiovascular Diseases Research) to the University of Texas Southwestern Medical Center for a Type 1 hybrid effectiveness-implementation, multi-center randomized controlled trial evaluating a polypill-based strategy for post-acute coronary syndrome (ACS) management. The five-year award, initiated August 5, 2025, and scheduled for completion July 31, 2030, addresses...
- Federal Grant Award Summary The University of Texas Southwestern Medical Center received a $1.53 million Project Grant from the National Heart, Lung, and Blood Institute (NHLBI) under the Cardiovascular Diseases Research program (CFDA 93.837), effective August 25, 2025, through May 31, 2029. The award funds basic biomedical research investigating the molecular mechanisms of atherosclerosis, specifically examining how endothelial cells regulate Scavenger Receptor Class B Type I (SR-BI) expression...
- Federal Project Grant Award Summary The National Heart, Lung, and Blood Institute (NHLBI) awarded the University of Alabama at Birmingham $223,438 on September 4, 2025, under the Cardiovascular Diseases Research program (CFDA 93.837) to conduct a clinical research study examining hypertension incidence in people with HIV initiating antiretroviral therapy (ART). The project, scheduled for completion by August 31, 2027, will assess blood pressure outcomes in ART-naïve individuals starting either...
- Federal Grant Award Summary The University of Connecticut Health Center received a $155,452 Project Grant from the National Heart, Lung, and Blood Institute (NHLBI) under the Cardiovascular Diseases Research program (CFDA 93.837), awarded July 1, 2026, with a completion date of June 30, 2031. This award funds research evaluating the epidemiological impact and cost-effectiveness of integrated HIV and non-communicable disease (NCD) service delivery in Zambia. The project leverages data from a...
- Federal Grant Award Summary The University of Washington's Office of Sponsored Programs received a $179,720 Project Grant from the National Heart, Lung, and Blood Institute (NHLBI) under the Cardiovascular Diseases Research program (CFDA 93.837), awarded January 30, 2026, with completion targeted for July 30, 2027. The project delivers a mixed-methods research investigation examining barriers to glucagon-like peptide-1 receptor agonist (GLP-1RA) utilization among rural patients with...
- Federal Grant Award Summary The National Heart, Lung, and Blood Institute (NHLBI) awarded a $794,406 Project Grant to the University of Texas Health Science Center at Houston, effective July 1, 2026, through June 30, 2031, under the Cardiovascular Diseases Research program (CFDA 93.837). The award funds the optimization and rigorous evaluation of a multifaceted implementation strategy designed to increase adoption and sustainability of evidence-based classroom physical activity approaches in...